PRESENTATION TYPES
- Featured Communication (Oral Presentation 15 min)
- Data Blitz (Oral Presentation 6 min)
- Poster Presentation in the Networking Area
- Poster Displayed in the Networking Area
TIMELINE
September 15, 2025: Abstract Submission OPEN
January 12, 2026 at 23:59 CET: Abstract Submission CLOSED
February 5, 2026: Abstract Acceptance Notification
March 31, 2026 at 23:59 CET: Congress Registration Deadline for Abstract Submitters
February 10, 2026: Late Breaking Abstract Submission Open
February 24, 2026 at 23:59 CET: Late Breaking Abstract Submission Deadline
March 13, 2026: Late Breaking Abstract Acceptance Notification
KNOW BEFORE YOU SUBMIT
- There is no fee for submitting an abstract.
- Abstracts will be accepted in English only.
- Each presenting author may submit a maximum of two abstracts.
- Abstracts must not exceed 500 words.
- A table or picture will count as 150 words. Maximum upload: 1 table and 1 picture.
- Each picture must have alt text (a brief description of the image content).
- The total word count includes tables, pictures, and alt text. However, it does not include the title, author details, or references.
- The presenting author is responsible for passing on information to co-authors.
- CINP recommends using the NbN nomenclature for psychotropics (http://nbn2r.com)
- The Abstracts will be reviewed and selected by the International Scientific Programme Committee.
- Abstract submissions are required to follow this structure:
- Background
- Aims & Objectives
- Method
- Results
- Discussion & Conclusion
CINP 2026 welcomes the submission of encore abstracts (abstracts previously presented at other scientific conferences or meetings). To be considered, encore abstracts must align with the congress’s thematic focus and adhere to the submission guidelines. Authors are kindly asked to disclose the original presentation venue and date during the submission process to ensure transparency.
The abstracts will be published in the CINP 2026 Abstract Book that will be available online at IJNP / Oxford University Press.
Topic 1 Research
Clinical
Preclinical
Translational
Other
Topic 2 Disorder
Addiction Disorders
Anxiety Disorders
Attention Deficit Disorders
Autism
Bipolar Disorders
Childhood & Adolescent Disorders
COVID-19
Dementia
Depression
Eating Disorders
Epilepsy
Neurodegenerative disorders
Obsessive-Compulsive Disorders
Pain
Panic Disorders
Personality Disorders
Post-Traumatic Stress Disorders
Premenstrual Dysphoric Disorder
Schizophrenia
Sexual Disorders
Sleep Disorders
Suicide
Other
Topic 3 Drug Methodology
Animal Models
Brain Stimulation
Cation channel blockers and Lithium
Computational Neuroscience
Dopamine blockers
Dopamine enhancers
Dopamine partial agonists
Ethics of Psychopharmacology
GABA enhancers
Genetics
Glutamate blockers
Glutamate enhancers
History of Psychopharmacology
Imaging
Molecular Neurobiology/Pharmacology
Monoamine blockers
Monoamine enhancers
Monoamine modulators
Neuropathology/Post-Morten Studies
Neurophysiology
Norepinephrine blockers
Oriental Medicine
Pharmacoeconomics
Pharmacogenetics/Kinetics
Psychoneuroimmunology
Serotonin 2A agonists
Serotonin blockers
Transcultural Psychopharmacology
Other